TriSalus Life Sciences Exceeds 2025 Revenue Guidance, Projects Strong 2026 Growth
Summary
TriSalus Life Sciences announced preliminary unaudited financial results, reporting strong revenue growth for Q4 and full-year 2025 that exceeded prior guidance, and issued positive revenue guidance for 2026.
Key Events
-
Exceeded 2025 Revenue Guidance
Reported preliminary full-year 2025 revenue of approximately $45.2 million, representing 53% year-over-year growth, surpassing the company's 50% annual growth guidance.
-
Strong Q4 2025 Revenue Growth
Announced preliminary fourth quarter 2025 revenue of approximately $13.2 million, a 60% increase year-over-year and 14% sequential quarterly growth.
-
Positive 2026 Revenue Guidance
Set initial 2026 revenue guidance in the range of approximately $60 million to $62 million, indicating continued significant growth.
-
Cash Position Update
Estimated cash and cash equivalents of approximately $20.4 million as of December 31, 2025, reflecting a $2.3 million reduction during Q4 2025.
Analysis
The preliminary financial results indicate robust commercial performance, with full-year 2025 revenue surpassing the company's 50% growth target. The initial 2026 revenue guidance projects continued significant growth, reinforcing confidence in the company's strategic initiatives and product adoption. While cash and cash equivalents saw a modest reduction in Q4, the focus on operational efficiency alongside strong revenue growth suggests a manageable financial trajectory. Investors should monitor the final audited results and the company's progress towards its 2026 revenue targets.
At the time of this filing, TLSI was trading at $5.80 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $306.8M. The 52-week trading range was $3.42 to $7.95. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.